ChrysCapital Fund X: $2.2B Raised in Six Months
Independent report content
INDEPENDENTPEFUNDANALYSIS
ChrysCapital Fund X India-Focused Private Equity Growth & Buyout $2.2B · Vintage 2025 Rank #1 of 100 June 25, 2026
FUND ChrysCapital Fund X | Type: India-Focused PE | Size: $2.2B | Vintage 2025
(final close Nov 2025) STR AT EGY Growth + Buyout | Sectors: Consumer · BFSI · Healthcare · Enterprise Tech · Industrials T R AC KRECORD Net IRR (prior funds): 25%+ confirmed | DPI: $7.8B from $5.5B deployed = 3.0x ROI | 80 exits, 14-15 IPOs
FUNDRAISE Closed in 6 months (industry avg 24+ months) | Ticket: $10M+ (Family Offices
only) | Access: Co-invest only (main fund closed) PEERSCOM PA RED Kedaara Capital Fund IV ($1.7B) | Everstone Capital Fund V (~$700M) | True North Fund VII (forming) SCORE 95/100 (Tier 1 — #1 ranked India PE fund) | Firm: $10B+ across 10 funds, 25- year track record Rupeia Signal Bar — Five Dimensions, Independently Assessed
GP QUALITY
10/10
TRACK RECORD
9/10
STRATEGY
9/10
LP TERMS
8/10
ACCESS
Restricted
THEACCESSPROBLEM
Fund X is CLOSED. Main fund LP positions are not available. The only current entry point is co-
investment alongside ChrysCapital in specific deals — requiring an existing relationship, a ~$10M
minimum ticket, and family-office or institutional status. This is not a fund a new LP can access today through standard channels.
★ EXECUTIVE DECISION SUMMARY
ChrysCapital Fund X is India's strongest private equity fund by every measurable metric —
track record, DPI quality, team stability, fundraise speed, and LP quality. The $2.2B fund
(largest-ever India-focused PE raise) closed in 6 months against a global backdrop where most
RUPEIA CHRYSCAPITAL FUND X VS PEERS INDEPENDENT PE FUND ANALYSIS
THE BOTTOM
LINE PE funds take 2+ years. Same strategy for 25 years, $7.8B in exits on $5.5B deployed, 10 consecutive funds without strategy drift. The catch: Fund X is closed; the only entry is co-
investment, requiring relationship, ~$10M ticket, and family-office/institutional status.
WHICH
INVESTOR
Access this fund IF you are a family office with Rs 200+ Cr investable corpus, existing PE- intermediary relationships, patience for a 7-10 year lockup, and comfort with $10M+ minimums. The co-invest route requires you already know the fund or come via a trusted placement agent. Access the peers instead IF you reach PE through SEBI Category II AIF format — Kedaara
Fund IV (closed), Everstone Fund V (open for co-invest, IFC-backed), True North Fund VII
(forming, smaller ticket via Indian LP route).
COMFORT FIT
ChrysCapital = Rolls Royce. Highest conviction, 25-year track, largest India PE exits — but entry is almost impossible for new LPs. Kedaara = BMW 7 Series. Operating-partner driven, IPO-exit focused, accessible for similar LP profiles.
Everstone = Mercedes E-Class. Mid-market, healthcare/tech, India+SEA, OPEN now with IFC participation. True North = Audi A6. Oldest India-only PE, mid-market control, forming now — early LP window.
THE RUPEIA
NUMBER
ChrysCapital Fund X closed in 6 months. The global average is 24+ months. That 18-month gap is the most powerful signal in PE fund analysis: LPs who took 2+ years to say yes to other funds said yes to ChrysCapital before other managers had finished their roadshows. This is not a
fundraise metric — it is a trust and track-record metric. No other India-focused PE fund has
achieved this close speed at this size.
RUPEIA INVESTMENT INTELLIGENCE | JUNE 25, 2026 | PE FUND REPORT #001 OF 100 | PREPARED INDEPENDENTLY
1 FUND SNAPSHOT — CHRYSCAPITAL X VS THREE PEERS
DIMENSION CHRYSCAPITAL X KEDAARA IV EVERSTONE V TRUE NORTH VII
Fund Size $2.2B $1.7B ~$700M TBD (forming)
Vintage / Close 2025 (Nov final close) 2024 (Apr final close) 2025 (active deployment) 2025-26 (forming)
Fund Type PE Growth + Buyout PE Growth + Buyout PE Growth + Buyout PE Buyout
(majority/minority) Geography India-focused India-focused India + Southeast Asia India-only
Sectors Consumer · BFSI · Healthcare · Tech ·
Industrials Mid-market consumer · BFSI · healthcare Healthcare · Tech · Consumer · Fin Services · Industrials Consumer · BFSI · Healthcare · Technology Ticket size (fund)
$75-300M per deal $75-200M per deal $40-150M per deal (mid-
market control)
$50-300M per deal LP min ticket $10M+ (FO only) $10M+ (institutional) $10M+ (co-invest); OPEN ~Rs 1 Cr (via Indian AIF route)
RUPEIA CHRYSCAPITAL FUND X VS PEERS INDEPENDENT PE FUND ANALYSIS
DIMENSION CHRYSCAPITAL X KEDAARA IV EVERSTONE V TRUE NORTH VII
AIF Category Offshore (Mauritius); Indian co- invest route Offshore (Mauritius); Indian Category II Offshore (Singapore); Indian Cat II via IFC route Category II AIF (Indian LP focus)
Management fee 2% p.a. est. 2% p.a. est. 2% p.a. est. 2% p.a. est. Carry 20% over hurdle (est. 8%) 20% over hurdle 20% over hurdle 20% over hurdle (100% catch-up)
Status CLOSED. Co-invest only. CLOSED. Co-invest window. OPEN — deploying Fund V FORMING — early LP window Target net IRR 25%+ (prior fund confirmed) 22-28% est. 20-25% gross; net ~18-22% 25% est. (historical avg) LP quality Global pensions, insurers, SWFs, Japanese institutions, ME FOs, US asset managers CDPQ, GIC, Allianz, HarbourVest, Univ. of Minnesota endowment IFC ($60M), Goldman Sachs, family offices, Asian institutions ADB (Fund VI); Indian LPs targeted for Fund VII Firm AUM $10B+ (10 funds, 25 yrs) $5.6B (4 funds, 15 yrs) $8B+ (Group, incl. RE, credit)
~$2-3B est. (all funds, 25 yrs)
2 GP QUALITY & TEAM ANALYSIS
TEAMS TA BILITY — THEMOSTIMPOR TA NTPESELECTIONCRITERION
In PE, the fund raises money on the strength of the people. The first question Rupeia asks is not "what is the track record?" but "are the people who built that track record still here?" A GP that raised on the strength of departed partners is raising on borrowed credibility. TEAM
DIMENSION CHRYSCAPITAL KEDAARA EVERSTONE TRUE NORTH
Founding year 1999 (25 yrs) 2011 (15 yrs) — ex-McKinsey, ex- Temasek team 2006 (20 yrs) — Sameer Sain + Atul Kapur 1999 (25 yrs) — founded as India Value Fund Advisors (IVFA)
Key partners (current) Saurabh Chatterjee (MD), Ashish Dhawan (founding, still involved), Ankur Sehgal Manish Kejriwal (Founder/MP, ex-Temasek India head), Sunish Sharma, Nishant Sharma Sameer Sain (Founder/CEO), Atul Kapur (Founder), Avnish Mehra (VC); 53 total Vishal Nevatia (CEO), Divya Sehgal (exits), 58 team incl.
20 partners Team stability signal Stated "long average partner/MD tenures" as the #1 reason for the 6-month close.
Rare in Indian PE. 40 execs incl. 24 investment pros. McKinsey-foundation process discipline. Built to scale.
20 partners, 53 total. "Mid-
Market Firm of the Year in
Asia" 4×. Goldman Sachs co- investor. 58 members. IVCA "Best Exit Performance 2024." Recent senior departure flagged (CBInsights Jun 2025).
Operating
partners Not explicitly disclosed. Investing-first firm. DISTINCTIVE: senior team of former CEOs — hands-on operational improvement.
Kedaara's primary differentiator. Arun Krishnamurthi listed. $2B returned in 5 yrs. Medical-devices focus.
Not explicitly listed. Control-deal focus implies board influence; ops depth less clear than Kedaara.
Attribution
risk
LOW — founding team active; 10 funds without key departure LOW-MED — three-founder
structure; loss of any one is
material MEDIUM — founders active but 20-yr firm has had departures MEDIUM — recent senior departure; verify bench depth Rupeia assessment Strongest team continuity in Indian PE. 25 years, same
strategy, same people.
Best operating-partner depth in peer group. Value-creation engine is genuine. Strongest cross-border network (India+SEA+US).
Most diversified capital base. Longest India-only PE track (25yr). Strongest exit discipline. Fund VII bench needs verification.
RUPEIA CHRYSCAPITAL FUND X VS PEERS INDEPENDENT PE FUND ANALYSIS
3 TRACK RECORD ATTRIBUTION & DPI QUALITY
RUPEIAMETHODOLOGY
For PE funds, track record must be disaggregated into: (1) who made the specific deals that generated
returns; (2) whether exits were cash-realised or paper TVPI; (3) whether the fund size at the time of the
track-record deals was comparable to the current fund. A $200M fund returning 4x is different from a $2B
fund needing to return 4x.
METRIC CHRYSCAPITAL KEDAARA EVERSTONE TRUE NORTH
Historical DPI (cash returned) $7.8B on $5.5B deployed = 3.0x cumulative ROI. 80 exits.
CONFIRMED across multiple
sources.
Fund I (2013, $542M): ~40% gross
IRR to Mar 2024 (Nishant Sharma, Bloomberg). Funds III- IV partially deployed. $2B+ returned in last 5 yrs (Avnish Mehra, Outlook
Business 2024). Funds III-
IV exit focus. Best Exit Performance 2024 (IVCA). Fund VI (2019, $50- 150M tickets). Niva Bupa + Biocon Biologics headline exits.
Exit quality classification 14-15 IPOs (Mankind Pharma, NSE, Awfis). Strategic: GeBBS Healthcare (US buyer Sep 2024).
Strategic + IPO = highest-quality mix. IPO-first. Vedant Fashions (Manyavar), Spandana, Vijaya Diagnostics. Vishal Mega Mart pipeline.
Secondary as base case (stated). IPO supplementary. Realised cash but valuation depends on credit conditions.
IPO-focused. IVCA award implies verified cash exits. Sesa Care (Oct 2024). Control = clean full exits.
Value creation attribution Pharma 3-9x across Intas, Mankind (independently confirmed). 25-yr sector consistency = real attribution, not vintage luck.
Fund I 40% gross IRR. Operating
partners drove margin improvement at portfolio cos. Healthcare 70-80% of
investments. Medical
devices + tech services. Goldman Sachs co- investor. Control model: majority/large minority, management upgrade, IPO exit. Niva Bupa became India's leading standalone health insurer.
Fund size vs
track compatibility
Fund X ($2.2B) is 60% larger than
Fund IX ($1.35B). KEY
QUESTION: can it deploy $2.2B at the same IRR? Requires larger or more deals. $542M→$1.1B→$1.7B; each step 50-60%. Fund IV checks $75- 200M.
Fund V size not public;
IFC $60M implies ~$600- 900M. Consistent with mid-market discipline.
Fund VI $50-150M tickets.
Fund VII: 14-15 investments
incl. digital at $25-50M — new addition, attribution
risk.
Rupeia DPI verdict
HIGHEST CONFIDENCE. $7.8B
from $5.5B is verifiable. 80 exits over 25 yrs = DPI real, diversified, not one-deal dependent.
HIGH on Fund I. Funds III-IV building. Operating-partner edge should sustain returns. MEDIUM. $2B in 5 yrs strong but self-reported.
Secondary preference = some DPI from PE-to-PE. HIGH on exit discipline (IVCA). Fund VII is a new vintage; digital additions add uncertainty.
4 STRATEGY TRUTH VS PORTFOLIO REALITY
DOESDEPLOYMENTM AT CHTHEPROMISE ?
Stated strategy and actual deployment often diverge. The premium PE question: does the actual portfolio match what was promised to LPs at fundraise? Strategy drift — moving from stated sector to opportunistic — is the most common unexplained risk in PE fund analysis.
DIMENSION CHRYSCAPITAL KEDAARA EVERSTONE TRUE NORTH
Stated strategy Majority + minority in strong-
governance businesses with clear
growth levers, IPO exit visibility. Consumer, BFSI, Healthcare, Tech, Industrials. Growth-oriented strategic + minority. Operationally- oriented, former-CEO
operating team. Consumer +
BFSI adjacent. Mid-market control growth. Cross-border India + SEA. Healthcare, tech, consumer, fin services, industrials.
Control preferred. Control (~2/3 historical). Mid-sized profitable India-centric businesses.
Digital-first additions for
Fund VII.
RUPEIA CHRYSCAPITAL FUND X VS PEERS INDEPENDENT PE FUND ANALYSIS
DIMENSION CHRYSCAPITAL KEDAARA EVERSTONE TRUE NORTH
Actual deployment Consumer (FMCG/retail/D2C), BFSI (Axis Bank, NSE), Healthcare (Intas, Mankind), IT (LTI, KPIT, GeBBS).
Consistent across 10 funds. Vedant Fashions, Spandana, Vijaya Diagnostics, AU SFB, Forest Essentials pipeline.
Consumer + BFSI dominant. Apothecon pharma ($270M Apr 2026), Wingify (SaaS $150M Apr 2026), Qlar Group (industrial tech, May 2026).
Niva Bupa, Biocon Biologics, iLink Digital, Sesa Care. BFSI + healthcare dominant; digital new layer.
Strategy drift
risk
LOW — 25 yrs, same sectors, same approach. 10 funds without drift. Strongest no-drift signal in Indian PE.
LOW-MED — core thesis consistent; US-India corridor is scope expansion, not drift, but adds complexity.
LOW — healthcare/tech consistent. Cross-border structural. Medical-devices sub-focus within healthcare.
MEDIUM — Fund VII digital at $25-50M is smaller than $50-300M. Two-tier strategy = material change.
Fund size
discipline 60% jump Fund IX→X. Requires avg
deal $100-150M+ or more deals.
Primary execution risk. Mgmt states they are increasing deal size, not count. 55% jump III→IV. Explicit $75-200M checks. 4 deals/yr target.
IFC $60M implies $600-900M. Mid-market control $40-150M unchanged.
Fund VII size TBD. 14-15
investments = 50-70%
more deals than prior. Execution stretch. Rupeia
strategy
verdict Strongest strategy consistency in Indian PE. No drift in 25 yrs. Fund size jump the only question — and they're sizing up deals, not count.
Strong. Operating-partner model genuinely differentiated. Watch first US-linked investment for discipline.
Consistent healthcare + tech thesis. Medical-devices import substitution is India- macro-aligned.
Fund VII digital-first
additions are the biggest question. Two-tier
strategy needs two partner
teams — verify attribution.
5 ENTRY VALUATION DISCIPLINE — WHAT THE FUND PAYS TO
GET IN
THEMOSTUNDERR AT EDPEMETRIC
Returns are set at entry, not at exit. A fund that consistently overpays for quality
companies will underperform a fund that pays disciplined prices for the same quality. Entry valuation discipline is the best single predictor of PE returns — and the hardest to verify from public information.
FACTOR CHRYSCAPITAL KEDAARA EVERSTONE TRUE NORTH
Typical entry
EV/EBITDA
Not disclosed. Pharma historically 8-15x (Intas, Mankind); consumer 15-25x (market-leader premium).
Fund X deals suggest larger
transactions.
Mid-market. Entry at EBITDA Rs 100-250 Cr. $75-200M checks suggest entry EV $300-800M / 10-20x.
Explicit: enter at EBITDA Rs 100-250 Cr, exit at Rs 400-500 Cr (Mehra). Mid-
market control likely 8-15x
entry. Control-oriented $50-300M ticket. Mid-market India. Multiples not disclosed; control-premium logic applies.
Cycle sensitivity Raised 2024-25. Post-2022 correction = more reasonable multiples. Consumer moderated; pharma still rich.
Closed Apr 2024 — good entry timing. Consumer+health intersection (Forest Essentials type).
Deploying 2025-26: Apothecon, Wingify, Qlar. Three 2026 deals = confident environment.
Forming. Early LP commits = post-correction entry. Best vintage for entry discipline.
Cheap vs good deal Explicit: "cheap deals don't automatically equate to good
investments." Pays premium for
market leaders with IPO visibility.
Quality-over-price.
Operating model lets them pay
growth multiples — EBITDA improvement lowers effective entry multiple post- improvement.
Control + IPO/secondary exit. Entry at mid-market private-vs-public discount. Healthcare trades below listed comps.
Control = negotiated entry with governance rights. Control premium offset by operational improvement + multiple expansion.
RUPEIA CHRYSCAPITAL FUND X VS PEERS INDEPENDENT PE FUND ANALYSIS
FACTOR CHRYSCAPITAL KEDAARA EVERSTONE TRUE NORTH
Vintage risk MODERATE. Deploys 2025-28. Strong IPO market. But $2.2B needs 14-20 deals at $100-150M — pace depends on deal-flow quality.
MOD-LOW. Good entry timing.
Operating model reduces
valuation sensitivity. 4 deals/yr
disciplined. LOW-MOD. Active deployment with IFC. Healthcare private-to-public discount = structural advantage.
LOW for Fund VII LPs. No deployment yet = post- correction entry. Risk is execution, not entry price.
6 VALUE CREATION BRIDGE — WHAT ACTUALLY DRIVES
RETURNS
OPER AT IONALALPHAVSMARKETTIMING
The PE return bridge separates real operational alpha from financial engineering and market timing. A
fund returning 3x on multiple expansion (buy at 8x, exit at 14x) is in a different risk category from one
returning 3x by improving EBITDA from Rs 100 Cr to Rs 300 Cr at the same multiple. The first is market-
dependent and less repeatable. The second is operational and more repeatable.
VALUE
DRIVER CHRYSCAPITAL KEDAARA EVERSTONE TRUE NORTH
Revenue growth Network introductions, management upgrades, distribution expansion.
Intas/Mankind grew via product launches; consumer distribution- led.
Operating partners "de-
bottleneck growth." Vedant Fashions via store rollout; NBFC via branch expansion. Healthcare grown via M&A consolidation (Apothecon).
Tech (Wingify) via product. Cross-border to US/SEA. Mid-market scaled. Niva Bupa small insurer → market leader via distribution. Biocon Biologics biosimilar pipeline.
Margin expansion
Governance + professionalization
typically +3-5pp EBITDA margin. Healthcare exits 3-9x suggest operational improvement. STRONGEST. Former-CEO
operating team focused on
margin. "EBITDA de- bottlenecking" thesis. Source of higher effective IRR. Explicit: buy at EBITDA Rs 100-250 Cr, exit Rs 400-500 Cr. 2-4x EBITDA improvement at constant multiple.
Take control, install management, improve
governance. Niva Bupa loss
ratios improved post- professionalization. Multiple expansion Significant historically. Mankind IPO (2023) at 35-40x earnings = expansion from PE entry.
IPO exit at expanded multiples (Vedant 40-50x PE). But edge is EBITDA improvement; multiple expansion additive.
Secondary may expand if buyer pays strategic premium. Healthcare private-to-public gap is primary source.
IPO at market multiples. Niva Bupa at 4-5x revenue for health insurance = strong expansion exit.
Deleveraging Primarily equity-only. No traditional LBOs. Growth PE = equity injection, not debt engineering.
Equity + some acquisition financing. Operating improvement drives deleveraging via FCF.
Some leveraged structures. Qlar (from Blackstone, May 2026) = "multi-step leveraged buyout." Everstone does use leverage.
May use acquisition financing. Mid-market control deals include some leverage, less than Western LBO.
Rupeia verdict Revenue growth + multiple expansion primary. 25-yr track proves repeatable. Limited
operating-improvement vs
Kedaara. Margin expansion from
operating partners = most
reliable, least market- dependent. Best value engine in peer group. EBITDA expansion + mid-
market discount +
IPO/secondary premium. Medical-devices import- substitution tailwind. Control + professionalization + IPO = disciplined. Longest history proves repeatability.
Digital adds uncertainty.
RUPEIA CHRYSCAPITAL FUND X VS PEERS INDEPENDENT PE FUND ANALYSIS
7 GROSS-TO-NET RETURN BRIDGE — WHAT THE LP
ACTUALLY RECEIVES
THENUMBERINVESTORSRARE LY CALCUL AT E
Fund managers always lead with gross IRR. LPs receive net IRR after management
fees, carry, expenses, taxes and currency effects. The gap between gross and net can be 5-10 percentage points. Rupeia calculates the net for each fund.
COMPONENT CHRYSCAPITAL KEDAARA EVERSTONE TRUE NORTH
Target gross IRR 30-35% est. (delivers 25%+ net per track) 35-45% gross est. (Fund I 40% to Mar 2024)
25-30% gross est. 28-35% gross est. (net 25%+ stated) Management fee drag 2% p.a. on committed; ~$330- 400M over fund life on $2.2B 2% p.a.; ~$340M on $1.7B over ~10yr 2% p.a.; ~$140M on ~$700M.
Smaller fund, smaller absolute drag. 2% p.a. on smaller Indian LP base. Rs-denominated = no currency mismatch.
Carry structure 20% over hurdle (est. 8%), full catch-up 20% over hurdle 20% over hurdle (IFC requires
market-standard)
20% over 100% catch-up (standard Indian Cat II) Currency effect USD fund; INR LP returns after ~3-4% pa Rs depreciation. "25%+ net" likely USD; INR-equivalent ~28-29%.
USD for offshore LPs; Indian AIF route = INR
returns without
conversion loss. Offshore Singapore. Same currency effect; Indian AIF route likely available.
Fund VII targets Indian LPs.
INR-denominated = no currency risk. Clean INR-to- INR. Tax (Indian LP) Offshore: Sec 9A pass-through for eligible funds; feeder LTCG 10% / STCG 15%. Complex for individuals.
Same offshore complexity. Cat II route: Sec 115UB pass-through; LTCG 10% after 1 yr.
Same as Kedaara. Cat II AIF: standard LTCG pass-through. CLEANEST. Cat II AIF = standard Indian tax. Sec 115UB. No offshore complexity.
Net IRR to Indian LP 25%+ net (USD); ~28-29% INR- equiv; ~25% post-LTCG. Strong.
18-22% net (USD); 21-25% INR; 19-23% post-tax. Strong. 17-21% net (USD); 20-24% INR; 18-22% post-LTCG.
Adequate. 20-23% net INR (no currency drag); 18-21% post-tax. Competitive.
Rupeia net verdict Best gross-to-net preservation:
market-standard fees, highest
gross. 3.0x DPI proves net delivery. Second-best. High gross + standard carry = strong net. Operating model = predictable net.
Adequate for risk. 20-22% net mid-market healthcare competitive. Use Cat II feeder if available.
Best net for Indian resident: INR + no currency drag + LTCG pass-through = lowest friction. 20-21% post-tax.
8 EXIT QUALITY & DPI REALITY
DIMENSION CHRYSCAPITAL KEDAARA EVERSTONE TRUE NORTH
Primary exit route IPO (14-15 listed) + strategic (GeBBS, pharma). Best mix — two independent routes.
IPO-first. Vedant, Spandana, Vijaya, AU SFB. "Don't over- optimize" (Nishant Sharma). Secondary PE sale base case + IPO supplementary. Medical devices targeted for IPO.
IPO-focused. IVCA "Best Exit Performance 2024." Sesa Care (Oct 2024). Niva Bupa listed.
Named exits (verified) Intas, Mankind (2023 IPO), GeBBS (Sep 2024), Infogain, NSE, Awfis (2024), Axis Bank, L&T Infotech, Spectramind.
Vedant Fashions, Spandana, Vijaya Diagnostic, AU SFB (2017, still performing), ASG Eye Hospitals (merger Oct 2025).
$2B+ in 5 yrs. Wingify (partial, Apr 2026), EverYondr (exit May 2026, PitchBook), IndoSpace (CPPIB + GLP).
Sesa Care (Oct 2024), Niva Bupa (IPO), Biocon Biologics (demerger). Multiple undisclosed.
RUPEIA CHRYSCAPITAL FUND X VS PEERS INDEPENDENT PE FUND ANALYSIS
DIMENSION CHRYSCAPITAL KEDAARA EVERSTONE TRUE NORTH
IPO-exit quality Mankind May 2023 = India's largest pharma IPO in years. NSE at premium. Highest cash DPI realisation.
Vedant (Manyavar) at Rs 35,000 Cr valuation. Vishal Mega Mart pipeline (potentially $1B). Strong.
Integris Health IPO by end- 2025. EverYondr May 2026. Healthcare creates strong IPO pipeline.
Niva Bupa + Biocon Biologics — high-multiple public sectors. IVCA award = independent quality validation.
Exit discipline flag Anticipates 4-5 IPOs "next 6-9 months" (from Nov 2025). Track which have listed — strong leading indicator.
3 IPOs targeted 2024-25 (Bloomberg). Track whether Vishal Mega Mart pipeline materialises.
Secondary-first reduces IPO dependency but adds PE- buyer dependency. If credit tightens, exit path narrows.
IVCA award strongest validation. Recent executive departure is the only flag — watch exit-focused partners.
9 CAPABILITY MATRIX — YES / NO / PARTIAL
CAPABILITY CHRYS X KEDAARA IV EVERSTONE V TRUE NORTH VII
25+ year India PE track record YES ? ? ? Confirmed 3x+ cumulative DPI (cash) YES ? PARTIAL PARTIAL
Operating partner team (real hands-on) NO YES PARTIAL PARTIAL
IPO as primary exit route YES YES PARTIAL YES Mid-market control deals PARTIAL YES YES YES Large-cap / market-leader deals YES PARTIAL NO PARTIAL India + Southeast Asia mandate NO NO YES NO Indian LP / Category II AIF access PARTIAL PARTIAL PARTIAL YES Open for new LP investment NO NO ? ?
Global pension fund LP base YES YES YES PARTIAL Healthcare sector specialisation PARTIAL PARTIAL YES PARTIAL BFSI / financial services specialisation YES YES PARTIAL YES Consumer goods / D2C focus YES YES PARTIAL YES Medical devices / manufacturing focus NO NO YES NO Digital-first / tech-native investments PARTIAL NO YES ?
Cross-border US-India investments NO ? YES NO Same strategy for 10+ consecutive funds YES ? ? YES YES (green) = independently confirmed. | PARTIAL (amber) = developing/caveated. | NO (red) = not present. | ? = insufficient public data.
RUPEIA' SCA PA BILITYREADING
No single fund wins all dimensions. ChrysCapital wins on track-record length, DPI confirmation, IPO exits, and LP quality. Kedaara wins on operating-partner depth and mid-market control. Everstone wins on healthcare specialisation, cross-border, and being the only fund currently OPEN. True North wins on Indian LP access, IVCA exit recognition, and best entry timing for Fund VII LPs. The matrix is how an investor decides which fund fits their specific need — not which is universally "better."
RUPEIA CHRYSCAPITAL FUND X VS PEERS INDEPENDENT PE FUND ANALYSIS
10 RISK ANALYSIS — FUND-LEVEL RED FLAGS & KILL
CONDITIONS
RED FLAG FUND EVIDENCE SEVERITY KILL CONDITION RESOLUTION
Fund size 60%
larger than prior fund ChrysCapital Fund IX $1.35B →
Fund X $2.2B
MEDIUM If Fund X cannot deploy in 3-4 yrs without compromising deal quality Monitor deal announcements from Nov 2025. No Fund X
deals in 18 months = flag.
Team attribution (first-ever risk) ChrysCapital Team stability cited as #1 LP selling point MEDIUM If any senior partner departs between close and deployment Monitor partner LinkedIn + firm announcements through deployment.
US expansion (new, untested) Kedaara Bloomberg May 2024: planning US office + senior hire MEDIUM If US-India deals fail to match prior India-only track Track whether any Fund IV capital is deployed in the US- India corridor.
Senior
executive
departure True North CBInsights Jun 2025 report MED-HIGH If the departing exec was primary deal-sourcer/exit
manager for Fund VI/VII
pipeline Request True North name the departed partner and confirm which Fund VI cos they led.
Secondary-sale exit preference Everstone VP Chairman: "secondary deal exit as base case" (Outlook
Business 2024)
MEDIUM If PE secondary market dries up (as in 2022): exit narrows, DPI slows Verify Fund V extension provisions. 10-yr fund in 2025 = exits needed by 2035.
Fund X not
open for new LPs ChrysCapital "Co-invest only" — main fund closed INFO If co-invest access is also restricted to existing relationships Engage via a known intermediary. Without relationship, co-invest access is functionally zero.
11 LP SIGNAL & RE-UP ANALYSIS
THEMOSTHONESTSIGNALINPE
LPs who re-committed to the next fund after receiving distributions from the prior
fund are the most credible validators of a PE manager. They voted with their capital
a second time, knowing the full track record. LP
SIGNAL CHRYSCAPITAL KEDAARA EVERSTONE TRUE NORTH
Global pension
fund LPs
Japan pensions, ME institutions, European asset managers — 30+ NEW
Fund X LPs. Existing also re-
committed. Oversubscribed (implied by 6-mo close). CDPQ, Allianz, HarbourVest, GIC (new in Fund IV).
Institutional depth rising each fund. Goldman Sachs (co-investor), IFC ($60M Nov 2025). IFC in
Funds III/IV/V — 3 consecutive
DFI re-ups. ADB (Fund VI). Indian LP targeting for Fund VII = strategic shift. Smaller intl base; 25-yr India-only track commands respect.
Re-up signal Most powerful: 6-month close, existing LPs re-committed instantly, 30+ new global LPs, $2.2B vs $1.35B = 60% growth while demand exceeded supply.
$1.1B → $1.7B. New LPs (GIC, Univ. Minnesota). Growth + new LPs each
fund.
IFC 3-consecutive re-up = most quantifiable signal. Each re-up = independent institutional re- underwriting.
ADB in Fund VI. Fund VII targeting Indian LPs — fewer intl re-ups possible. Domestic LP market is the key signal.
RUPEIA CHRYSCAPITAL FUND X VS PEERS INDEPENDENT PE FUND ANALYSIS
LP
SIGNAL CHRYSCAPITAL KEDAARA EVERSTONE TRUE NORTH
Fundraise
velocity 6 months to close $2.2B — ~10x faster than industry average. No comparable India PE fund has matched this at this size.
~12 months to close $1.7B. Fast for this size. Active deployment — not raising as of Jun 2026. IFC commitment Nov 2025.
Forming = pre-close. Fund VII started Sept 2025; ~12-18 months to close. Early LP window now.
Rupeia LP verdict STRONGEST. 6-mo close + 30 new global LPs + re-ups + 60% size increase = every LP signal positive simultaneously. Unseen in Indian PE before.
STRONG. 4 funds, growing LP quality, 3x IPO pipeline. Building a global LP franchise.
ADEQUATE. IFC 3× re-up institution-grade. Goldman co- invest signals deal quality. Secondary-exit preference is a structural limit.
ADEQUATE. ADB + IVCA
validate exits. Fund VII Indian LP strategy untested but structurally appropriate.
12 INVESTOR CLASS ANALYSIS — WHICH FUND FITS WHICH
INVESTOR
RUPEIASECTION — NOTARANKING
All four funds are strong by Indian PE standards. The question is which fund matches which investor's specific needs, constraints, and access reality. Read your investor type below. For Individual Investors / HNIs ChrysCapital Fund X is effectively inaccessible to individual investors outside the top tier of Indian family wealth — the $10M+ minimum and closed status make it a non-option. Of the four, True North Fund VII is the most accessible individual route — forming now, targeting Indian LPs, likely available through the Category II AIF route at Rs 1 Cr minimum if a domestic feeder is structured. The returns profile (25%+ target, IVCA-validated exit discipline, 25-year track) is comparable to ChrysCapital at far better accessibility.
Kedaara Fund IV is closed. Everstone Fund V has a co-invest window but still requires Rs 80+ Cr minimum. For individual HNIs with Rs 5-25 Cr to deploy in PE, the honest answer is that direct access to any of these four is not possible; the route is through a fund-of-funds or a SEBI-registered intermediary with existing relationships. Rupeia recommends: contact a SEBI-registered Category III AIF that feeds into one of these
managers, or wait for the True North Fund VII domestic AIF announcement.
For Family Offices (Rs 200+ Cr investable corpus) Family offices are the primary target LP audience for all four funds, but with different access dynamics. ChrysCapital co-invest is the highest-quality but requires an existing relationship — if you have it, prioritise getting on their Fund X co-invest list. Even a single co-investment alongside ChrysCapital (a Rs 15-25 Cr cheque alongside their Rs 400-800 Cr) gives direct exposure to their deal sourcing and diligence quality.
Kedaara Fund IV is closed, but their 4-deals-per-year pipeline means deal-by-deal co-investment may still be available with a relationship — and the operating-partner differentiator means Kedaara co-invests likely see post-investment improvement even at rich entry prices. Everstone Fund V is the most open of the four currently — IFC committed Nov 2025, Goldman Sachs as co-investor, mid-market healthcare/tech, $40-150M
deals; a family office co-investing Rs 15-30 Cr per deal gets mid-market control exposure with a 20-year
manager. True North Fund VII is the most Indian-LP-friendly and is forming now — the right moment to
RUPEIA CHRYSCAPITAL FUND X VS PEERS INDEPENDENT PE FUND ANALYSIS
engage as an anchor LP in the Indian AIF tranche. Anchor status (Rs 50+ Cr) typically secures co-invest rights, quarterly investment-team calls, and better fee structures. The 25-year track + IVCA exit award + mid-market India control is the strongest fit for a family office wanting a long-term PE relationship, not just one-time access.
For Institutions (CVCs, Pension Funds, Insurance Companies, Family Investment Offices) ChrysCapital Fund X is the correct allocation for a large institutional LP with $50M+ capacity and an existing India PE programme — the 6-month close, 30+ global LP additions, and $7.8B cumulative exits make it the benchmark allocation for any institution building an India PE book. The complication is timing:
Fund X is closed, and Fund XI will likely be raised in 2027-28, so institutions should build the relationship
now to ensure inclusion. Kedaara Fund IV has CDPQ, Allianz, GIC and HarbourVest as LPs — a peer group signalling the fund meets institutional diligence standards including ESG, governance and audit; for an institution that missed Fund IV, co-invest is the bridge until Fund V. Everstone Fund V is the most immediately accessible institutional option: IFC's $60M commitment (Nov 2025) signals MDB-level environmental and social due diligence — the highest institutional clearance available for an EM PE fund — and co-investing alongside IFC gives the best possible independent validation of deal quality. True North
Fund VII suits a smaller institutional allocation, best for an institution building India PE exposure for the
first time (Indian-LP-friendly, lower minimum, 25-year track). Pension funds with long-horizon mandates should consider True North Fund VII as an anchor alongside one larger future allocation (ChrysCapital XI or Kedaara V). For NRI Investors (UAE, Singapore, UK, US-based Indian diaspora)
NRI investors face the most complex access and tax environment of all classes for Indian PE. ChrysCapital, Kedaara and Everstone are all offshore funds (Mauritius or Singapore domicile); NRI participation offshore may face DTAA complexity, country-specific PFIC issues (US-based NRIs), and remittance documentation. True North Fund VII targets Indian domestic capital via the AIF route — which paradoxically may be more complex for an NRI depending on FEMA status and whether they hold NRI/OCI status with an Indian bank account. The cleanest NRI access routes are: (1) a GIFT City fund allowing international participation in Indian PE without domestic FEMA restrictions; (2) a well-structured NRI PMS or AIF that handles the compliance layer. None of the four is specifically positioned for NRI access. Practical recommendation: US- based NRIs should engage a US-based India-focused fund-of-funds (several exist in Silicon Valley and New York) that already holds LP positions in ChrysCapital and Kedaara; Singapore/UAE-based NRIs can use the offshore structure directly. SEBI Category II AIF via NRE/NRO account is legally possible but requires FEMA compliance documentation.
RUPEIA CHRYSCAPITAL FUND X VS PEERS INDEPENDENT PE FUND ANALYSIS
13 COMFORT FIT — THE DECISION PAGE
WHICHONEISRIGHTFORME ?
This page answers the single most important question for any investor comparing these four funds. The answer is not about which fund is best — it is about which fund fits your specific situation.
IF YOU WANT /
NEED… BEST FIT WHY CAUTION
Maximum return potential over 10 yrs (and you have access) CHRYSCAPITAL X 25-yr track, 3.0x cumulative DPI confirmed, 6-mo fundraise, India's largest PE fund. Highest-conviction allocation if accessible.
Main fund closed. Co-invest only. Requires existing relationship. Not accessible to new LPs without warm intro.
Actively managed operational improvement (hands- on PE)
KEDAARA IV The only fund here with a genuine
operating-partner team of former CEOs.
EBITDA improvement is structural and repeatable.
Fund IV closed; co-invest only. 40% gross
Fund I is gold standard but Fund IV is
much larger — performance may moderate. Currently open fund with institutional validation EVERSTONE V IFC committed Nov 2025. Goldman Sachs co-invests. Active 2026 deployment. Mid-
market healthcare/tech. OPEN for co-
invest and LP. Secondary-exit preference creates PE-
market dependency. India+SEA = not
pure India. Mid-market = smaller deals but more diversification. Indian LP-friendly
structure, best entry
timing TRUE NORTH VII 25-yr track, IVCA exit award 2024, forming now (pre-deployment = best vintage), Cat II AIF for clean Indian LP access, mid-
market control.
Fund size TBD. Digital-first additions
new and untested. Senior departure needs verification. Smaller LP base = less global validation. Minimum lock-up with PE-like return None of the four All are 7-10 yr closed-end PE funds. If you need liquidity in under 7 yrs, PE is structurally wrong for this capital.
Consider listed PE (Avendus, ICICI Pru) or PMS for more liquid PE-adjacent exposure. Healthcare-specific PE exposure EVERSTONE V 70-80% healthcare + tech. Medical-devices import substitution. Apothecon Pharma $270M (Apr 2026) most recent.
India healthcare PE increasingly crowded. 5-7 funds target the same deals. Everstone's edge is cross-border (India+SEA).
BFSI / financial services focus CHRYS or
KEDAARA
ChrysCapital: NSE, Axis Bank, pharma- adjacent BFSI. Kedaara: AU SFB, Spandana, NBFC focus. BFSI facing NPA-cycle concerns and RBI tightening (2024-25). Both diversified enough to manage; size sector risk accordingly.
Lowest management fee cost TRUE NORTH VII Smaller fund = lower absolute fee drag. Indian AIF = no offshore layer costs. Most cost-efficient net-to-gross.
Lower AUM = less LP diversification; more dependent on single fund relationship vs multi-LP governance pressure.
Co-investment alongside global PE (learning + access) CHRYS or KEDAARA co- invest Co-investing alongside ChrysCapital (Japan pensions, ME institutions) or Kedaara (CDPQ, Allianz, GIC) = exposure to global institutional diligence standards.
Requires existing relationship + $75- 200M fund minimum per deal plus your cheque. Realistic co-invest minimum: Rs 10-15 Cr per deal.
Earliest LP commitment with most leverage (fee, terms, co-invest)
TRUE NORTH VII Anchor LP in a forming fund gets best terms, co-invest rights, direct GP access, and often reduced carry on the initial amount.
Anchoring means lock-up before deployment — you own fund risk from day 1 without knowing the portfolio. Requires conviction in GP, not specific
deals.
RUPEIA CHRYSCAPITAL FUND X VS PEERS INDEPENDENT PE FUND ANALYSIS
14 RUPEIA FINAL INDEPENDENT VIEW
These are the four most credible India-focused PE funds available to a family office or institutional LP in June 2026. Ranking them by quality is misleading because each is best for a different investor situation. Ranking them by current accessibility, however, is useful: 1 True North Fund VII — Most accessible now Forming — early LP window open. Category II AIF. Indian-LP friendly. 25-year track. IVCA award.
RUPEIA CALL: ENGAGE NOW. THE FORMING WINDOW IS THE BEST ENTRY. LOCK IN ANCHOR LP TERMS BEFORE THE
FUND REACHES 50% CLOSE.
2 Everstone Fund V — Open with co-invest Active deployment. IFC-backed. Healthcare/tech focus. Goldman Sachs co-investor. Open for institutional LP.
RUPEIA CALL: EVALUATE. IFC COMMITMENT IS STRONG VALIDATION. CO-INVEST ROUTE IS REAL. HEALTHCARE
THESIS HAS 2- 3 YEAR VISIBILITY.
3 Kedaara Fund IV — Closed but co-invest pipeline Closed fund but 4 deals/year = co-invest opportunities. Best operating-partner team. 3 IPOs targeted 2024-25.
RUPEIA CALL: BUILD RELATIONSHIP. PRIORITY: GET ON KEDAARA'S CO-INVEST CALL LIST. DEAL-BY-DEAL CO-
INVEST AVAILABLE WITH WARM INTRODUCTION.
4 ChrysCapital Fund X — Closed, requires relationship Closed. Co-invest only. Requires existing LP or strong intermediary intro. Fund XI likely 2027-28.
RUPEIA CALL: PREPARE FOR FUND XI. IF YOU LACK A RELATIONSHIP, START BUILDING IT NOW VIA PORTFOLIO-
COMPANY ENGAGEMENTS, EVENTS, OR INTERMEDIARY INTRO. FUND XI IS THE MAIN LP ENTRY POINT.
RUPEIA CHRYSCAPITAL FUND X VS PEERS INDEPENDENT PE FUND ANALYSIS
THERUPEIANUMBERFORTHISREPORT
ChrysCapital closed Fund X in 6 months at $2.2B; Kedaara closed Fund IV in ~12 months at $1.7B — both faster than any comparable global benchmark. But the signal that actually matters for an investor deciding today is not the speed — it is who came back. IFC re-committed to Everstone for the 3rd consecutive time. CDPQ, Allianz, GIC and HarbourVest all re-committed to Kedaara. 30+ global LPs with no prior ChrysCapital relationship committed to Fund X after evaluating the 25-year track. These are not yield-chasing decisions — they are mission-critical capital allocations by institutions that employ entire India PE diligence teams. When institutions that can afford to say no choose to say yes, that is the most reliable signal available.
THEEAR LY SIGNAL — W H AT LINKEDINANDHEADCOUNTREVEAL
True North's senior executive departure (CBInsights Jun 2025) is the highest-priority active monitoring item in this report. If the departure was from the deal team (not ops), and if the departed partner was the primary contact for Fund VI portfolio companies in the IPO pipeline, that is a material risk to Fund VII's early track-record signalling. Recommended: check LinkedIn for the departed executive's current role and how many True North portfolio boards they sat on. If they are at a competitor fund or started their own vehicle, assess whether any portfolio relationship migrated with them. This 30-minute LinkedIn check may be the single most important diligence action before committing to True North Fund VII.
On the four funds individually: ChrysCapital is the benchmark — every India PE discussion starts with ChrysCapital as the quality standard. Kedaara is the best investment if you value operational alpha over access convenience. Everstone is the most accessible institutional-grade fund right now and its healthcare thesis is the most India-macro-aligned. True North Fund VII offers the most attractive entry timing (pre- deployment) and the most Indian-LP-friendly structure. None of these are wrong choices. The question is which one is right for you — and that answer lives in your liquidity timeline, your existing relationships, your minimum ticket, and your sectoral conviction.
RUPEIAVERDICT
All four funds are strong. ChrysCapital Fund X is the quality benchmark but is closed to new LPs — prepare for Fund XI (2027-28). For an investor who needs to act today, True North Fund VII (engage now, anchor terms) and Everstone Fund V (open, IFC-validated) are the two live entry points. Use the Comfort Fit page (Section 13) to match the fund to your situation; run the True North LinkedIn check (above) before committing there.
RUPEIA CHRYSCAPITAL FUND X VS PEERS INDEPENDENT PE FUND ANALYSIS
The Standard This report compares four India PE funds on GP quality, track-record attribution, DPI reality, entry discipline, value creation, exit quality and investor fit — all from public information. Where information was unavailable, the gap is named. The Comfort Fit page (Section 13) is the fastest path to a decision. The True North LinkedIn check is the most actionable immediate step. All four funds are strong. The question is which one is right for you.
DISCLAIMER
This document is published strictly for informational, educational, and academic record-keeping purposes only. The publisher of this document is not a SEBI Registered Investment Adviser (RIA), nor a SEBI Registered Research Analyst (RA). This report does not constitute personal investment advice, an independent research report, a financial recommendation, or an offer or solicitation to buy, sell, or subscribe to any securities. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.
